{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:24:36Z","timestamp":1761171876417,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":3764,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.farma.2010.10.008","type":"journal-article","created":{"date-parts":[[2011,4,24]],"date-time":"2011-04-24T17:34:12Z","timestamp":1303666452000},"page":"11-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluaci\u00f3n retrospectiva de la efectividad y seguridad de cinacalcet para el tratamiento de hiperparatiroidismo secundario dependiendo del valor basal de paratohormona intacta"],"prefix":"10.1016","volume":"36","author":[{"given":"G.","family":"Mercadal Orfila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Blasco Mascar\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2010.10.008_bib0005","unstructured":"Sociedad Espa\u00f1ola de Nefrolog\u00eda. Recomendaciones de la Sociedad Espa\u00f1ola de Nefrolog\u00eda para el manejo de las alteraciones del metabolismo \u00f3seo-mineral en los pacientes con enfermedad renal cr\u00f3nica [consultado 24\/04\/2010]. Disponible en: http:\/\/www.senefro.org\/modules.php?name=webstructure&idwebstructure=4182008"},{"key":"10.1016\/j.farma.2010.10.008_bib0010","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.farma.2010.10.008_bib0015","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.farma.2010.10.008_bib0020","unstructured":"NICE technology appraisal guidance 117. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end stage renal disease on maintenance dialysis therapy [consultado 14\/03\/2010]. Disponible en: http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=byID&o=116072007"},{"key":"10.1016\/j.farma.2010.10.008_bib0025","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"113","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.farma.2010.10.008_bib0030","unstructured":"Cinacalcet. Informe EPAR Agencia Europea del Medicamento (EMEA) [consultado 24\/04\/2010]. Disponible en: http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/mimpara\/emea-combined-h570es.pdf2004"},{"key":"10.1016\/j.farma.2010.10.008_bib0035","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney International"},{"key":"10.1016\/j.farma.2010.10.008_bib0040","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in Hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.farma.2010.10.008_bib0045","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2010.10.008_bib0050","first-page":"8","article-title":"Early use of cinacalcet (MIMPARA (R)\/SENSIPAR (R)) in dialysis patients enables greatest achievement of NKF-KDOQI (TM) treatment targets for bone metabolism","volume":"21","author":"Frazao","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.farma.2010.10.008_bib0055","doi-asserted-by":"crossref","unstructured":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201.","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"10.1016\/j.farma.2010.10.008_bib0060","first-page":"511","article-title":"[Is Cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?]","volume":"28","author":"Arenas","year":"2008","journal-title":"Nefrologia"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634311000778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634311000778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:16:53Z","timestamp":1761106613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634311000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1130634311000778"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2010.10.008","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluaci\u00f3n retrospectiva de la efectividad y seguridad de cinacalcet para el tratamiento de hiperparatiroidismo secundario dependiendo del valor basal de paratohormona intacta","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2010.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 SEFH. Published by Elsevier Espa\u00f1a S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}